VivoArchitect is a preclinical Contract Research Organization (CRO) specialized in in vivo mouse models for longevity and age-associated diseases. We provide research services for biotech companies, covering experimental design, ethical approval, study execution, and scientific reporting.
Products, services, technology
We provide preclinical CRO services using in vivo mouse models for longevity and age-related research, covering experimental design, animal experimentation ethics and regulatory approval, full study execution (treatment, phenotyping, sampling), data analysis, and scientific reporting.
Cooperation possibilities
We offer collaboration opportunities with biotech companies seeking to validate longevity therapies and with research institutions focused on aging research, providing preclinical in vivo studies and translational validation through service contracts and long-term partnerships.
- https://vivoarchitect.com/
- +41 76 544 60 26
- Send an email
- Alberto Parras
Some insights
Aging affects everyone, and living longer should also mean living healthier. Through our in vivo platform, we help identify and validate new longevity and anti-aging therapies that aim to improve healthspan and quality of life for humans.
We are proud to combine scientific excellence with integrity and long-term vision. VivoArchitect prioritizes reproducibility, ethics and impact over short-term profit, building close partnerships with our clients to deliver reliable, high-quality preclinical research.
We consider as role models those biotech companies, academic groups and CROs that set high standards in reproducibility, animal welfare and translational relevance, and that successfully bridge fundamental research with real-world clinical and societal needs.
Our key competitive advantage is a team with deep expertise in aging research, combined with extensive experience in in vivo studies and drug discovery, particularly in mice. We plan to integrate AI and advanced data technologies to enable synergistic, next-generation anti-aging therapies.
The Swiss biotech ecosystem can best support us by facilitating access to biotech clients and strategic partners that complement our in vivo services, such as in vitro, in silico, wet lab, and clinical capabilities we do not offer.
We aim to connect with drug discovery biotech and pharma companies, longevity-focused investors, academic researchers, and innovation hubs interested in preclinical research, aging, and healthspan-focused solutions.
